Zeng Y, Luo C, Lin G, Li F, Bai X, Ko J
J Clin Invest. 2025; 135(1).
PMID: 39744943
PMC: 11684818.
DOI: 10.1172/JCI182768.
Liu B, Wang R, He Y
Genet Res (Camb). 2024; 2024:5148918.
PMID: 39735594
PMC: 11671629.
DOI: 10.1155/genr/5148918.
Reffai A, Hori M, Adusumilli R, Bermudez A, Bouzoubaa A, Pitteri S
Cancers (Basel). 2024; 16(19).
PMID: 39409902
PMC: 11476039.
DOI: 10.3390/cancers16193282.
Arumugam T, Adimulam T, Gokul A, Ramsuran V
Front Immunol. 2024; 15:1422834.
PMID: 39355248
PMC: 11442197.
DOI: 10.3389/fimmu.2024.1422834.
Briercheck E, Ravishankar S, Ahmed E, Carias Alvarado C, Barrios Menendez J, Silva O
Blood Adv. 2024; 8(14):3731-3744.
PMID: 38815238
PMC: 11296253.
DOI: 10.1182/bloodadvances.2023012461.
Meta-analysis of Epstein-Barr virus genomes in Southern Chinese identifies genetic variants and high risk viral lineage associated with nasopharyngeal carcinoma.
Wong K, Hui K, Lam K, Kwong D, Lung M, Yang W
PLoS Pathog. 2024; 20(5):e1012263.
PMID: 38805547
PMC: 11161099.
DOI: 10.1371/journal.ppat.1012263.
Polygenic risk-stratified screening for nasopharyngeal carcinoma in high-risk endemic areas of China: a cost-effectiveness study.
Yang D, Miller J, Xue W, Tang M, Lei L, Zheng Y
Front Public Health. 2024; 12:1375533.
PMID: 38756891
PMC: 11097958.
DOI: 10.3389/fpubh.2024.1375533.
Association of TNFRSF19 with a TNF family-based prognostic model and subtypes in gliomas using machine learning.
Guo Y, Zhou Q, Wei M, Fan J, Huang H
Heliyon. 2024; 10(7):e28445.
PMID: 38560169
PMC: 10979244.
DOI: 10.1016/j.heliyon.2024.e28445.
Host genetic variants, Epstein-Barr virus subtypes, and the risk of nasopharyngeal carcinoma: Assessment of interaction and mediation.
Xu M, Feng R, Liu Z, Zhou X, Chen Y, Cao Y
Cell Genom. 2024; 4(2):100474.
PMID: 38359790
PMC: 10879020.
DOI: 10.1016/j.xgen.2023.100474.
Nasopharyngeal carcinoma: nationwide trends in subtype-specific incidence and survival over 3 decades in a non-endemic area.
van Velsen J, van der Vegt B, Plaat B, Langendijk J, Epskamp-Kuijpers C, van Dijk B
J Cancer Res Clin Oncol. 2024; 150(2):49.
PMID: 38285234
PMC: 10824861.
DOI: 10.1007/s00432-023-05547-8.
Machine learning in onco-pharmacogenomics: a path to precision medicine with many challenges.
Mondello A, Dal Bo M, Toffoli G, Polano M
Front Pharmacol. 2024; 14:1260276.
PMID: 38264526
PMC: 10803549.
DOI: 10.3389/fphar.2023.1260276.
Towards system genetics analysis of head and neck squamous cell carcinoma using the mouse model, cellular platform, and clinical human data.
Zohud O, Lone I, Nashef A, Iraqi F
Animal Model Exp Med. 2023; 6(6):537-558.
PMID: 38129938
PMC: 10757216.
DOI: 10.1002/ame2.12367.
EBV-induced T-cell responses in EBV-specific and nonspecific cancers.
Zhang Q, Xu M
Front Immunol. 2023; 14:1250946.
PMID: 37841280
PMC: 10576448.
DOI: 10.3389/fimmu.2023.1250946.
The Long Non-Coding RNA ANRIL in Cancers.
Sanchez A, Lhuillier J, Grosjean G, Ayadi L, Maenner S
Cancers (Basel). 2023; 15(16).
PMID: 37627188
PMC: 10453084.
DOI: 10.3390/cancers15164160.
Molecular Mechanisms and Risk Factors Related to the Pathogenesis of Peyronie's Disease.
Mitsui Y, Yamabe F, Hori S, Uetani M, Kobayashi H, Nagao K
Int J Mol Sci. 2023; 24(12).
PMID: 37373277
PMC: 10299070.
DOI: 10.3390/ijms241210133.
Feature Reviews of the Molecular Mechanisms of Nasopharyngeal Carcinoma.
Liao L, Hsu W, Chen C, Chiu Y
Biomedicines. 2023; 11(6).
PMID: 37371623
PMC: 10295754.
DOI: 10.3390/biomedicines11061528.
High-throughput identification of regulatory elements and functional assays to uncover susceptibility genes for nasopharyngeal carcinoma.
Wang T, Xiao R, He Y, Zhang W, Diao H, Tang M
Am J Hum Genet. 2023; 110(7):1162-1176.
PMID: 37352861
PMC: 10357478.
DOI: 10.1016/j.ajhg.2023.06.003.
Nasopharyngeal carcinoma ecology theory: cancer as multidimensional spatiotemporal "unity of ecology and evolution" pathological ecosystem.
Luo W
Theranostics. 2023; 13(5):1607-1631.
PMID: 37056571
PMC: 10086202.
DOI: 10.7150/thno.82690.
The impact of HLA polymorphism on herpesvirus infection and disease.
Palmer W, Norman P
Immunogenetics. 2023; 75(3):231-247.
PMID: 36595060
PMC: 10205880.
DOI: 10.1007/s00251-022-01288-z.
EBV-associated diseases: Current therapeutics and emerging technologies.
Chakravorty S, Afzali B, Kazemian M
Front Immunol. 2022; 13:1059133.
PMID: 36389670
PMC: 9647127.
DOI: 10.3389/fimmu.2022.1059133.